Table 1 Clinical factors related to actuarial overall survival of patients undergoing radiofrequency ablation for early‐stage hepatocellular carcinoma.
From: Conditional survival after radiofrequency ablation for early-stage hepatocellular carcinoma
Variables | Patient survival (%) | p | ||
|---|---|---|---|---|
1-year OS | 3-year OS | 5-year OS | ||
All patients | 96.3% | 72.3% | 59.7% | |
Women | 98.8% | 75.2% | 65.1% | 0.212 |
Men | 94.8% | 70.7% | 56.6% | |
BCLC stage 0 | 97.3% | 78.9% | 67.1% | 0.024 |
BCLC stage A | 95.7% | 68.1% | 55.0% | |
AFP < 20 ng/ml | 96.7% | 77.4% | 65.1% | 0.010 |
AFP ≧20 ng/ml | 95.5% | 64.1% | 51.1% | |
MELD score≦9 | 97.8% | 77.8% | 67.0% | < 0.001 |
MELD score > 9 | 94.1% | 63.9% | 48.0% | |
HBsAg negative | 95.6% | 69.8% | 55.2% | 0.074 |
HBsAg positive | 97.3% | 75.9% | 66.2% | |
Anti-HCV negative | 96.1% | 72.5% | 59.9% | 0.735 |
Anti-HCV positive | 96.5% | 72.1% | 59.6% | |
Age≦ 65 years | 95.9% | 73.5% | 63.3% | 0.051 |
Age > 65 years | 96.6% | 70.9% | 55.6% | |
